+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
ContraFect Corporation - logo

ContraFect Corporation is a biotechnology company that develops therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

From
From
From
From
From
From
From
From
From
From
Acinetobacter infections - Pipeline Insight, 2022 - Product Thumbnail Image

Acinetobacter infections - Pipeline Insight, 2022

  • Clinical Trials
  • February 2022
  • 80 Pages
From
Pseudomonal Infections - Pipeline Insight, 2022 - Product Thumbnail Image

Pseudomonal Infections - Pipeline Insight, 2022

  • Drug Pipelines
  • March 2022
  • 50 Pages
From
Bacteremia - Pipeline Insight, 2021 - Product Thumbnail Image

Bacteremia - Pipeline Insight, 2021

  • Clinical Trials
  • December 2021
  • 60 Pages
From
From
Pseudomonas Aeruginosa Infection - Pipeline Insight, 2021 - Product Thumbnail Image

Pseudomonas Aeruginosa Infection - Pipeline Insight, 2021

  • Clinical Trials
  • September 2021
  • 60 Pages
From
Loading Indicator